FY2024 EPS Estimates for AxoGen Raised by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN) – Stock analysts at Leerink Partnrs increased their FY2024 earnings per share estimates for AxoGen in a research report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will post earnings per share of ($0.31) for the year, up from their previous forecast of ($0.32). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for AxoGen’s Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.17 EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.34 EPS.

A number of other analysts have also recently weighed in on AXGN. JMP Securities upped their target price on shares of AxoGen from $17.00 to $20.00 and gave the company a “market outperform” rating in a research note on Friday, August 9th. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.00.

AxoGen Trading Up 3.4 %

Shares of AxoGen stock opened at $14.07 on Wednesday. AxoGen has a 52-week low of $5.55 and a 52-week high of $15.90. The firm has a market capitalization of $619.22 million, a PE ratio of -43.97 and a beta of 1.13. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The company’s fifty day moving average price is $13.70 and its two-hundred day moving average price is $10.76.

Institutional Investors Weigh In On AxoGen

Several institutional investors and hedge funds have recently made changes to their positions in AXGN. First Light Asset Management LLC grew its position in AxoGen by 336.6% during the 2nd quarter. First Light Asset Management LLC now owns 3,344,033 shares of the medical equipment provider’s stock worth $24,211,000 after acquiring an additional 2,578,147 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in AxoGen by 2,014.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,310,811 shares of the medical equipment provider’s stock worth $9,490,000 after purchasing an additional 1,248,823 shares in the last quarter. Divisadero Street Capital Management LP boosted its stake in AxoGen by 587.2% in the second quarter. Divisadero Street Capital Management LP now owns 686,994 shares of the medical equipment provider’s stock worth $4,974,000 after purchasing an additional 587,024 shares in the last quarter. Parkman Healthcare Partners LLC bought a new stake in shares of AxoGen during the third quarter worth $5,789,000. Finally, FMR LLC increased its stake in shares of AxoGen by 743.1% in the third quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock valued at $2,509,000 after buying an additional 157,730 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.